Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | Datopotamab deruxtecan with or without osimertinib - (TROPION-Lung15) | Metastatic Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| AstraZeneca PLC | Datopotamab deruxtecan plus osimertinib - (TROPION-Lung14) | EGFR mutated nonsquamous NSCLC | Phase 3 | Ongoing | Intravenous and oral | Oncology |
| AstraZeneca PLC | Datopotamab deruxtecan plus rilvegostomig - (TROPION-Lung10) | Previously untreated locally advanced or metastatic nonsquamous NSCLC | Phase 3 | Ongoing | Intravenous infusion | Oncology |
| AstraZeneca PLC | Imfinzi (durvalumab) - (VOLGA) | Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC) | Phase 3 | Ongoing | Intravenous | Oncology |
| AstraZeneca PLC | ULTOMIRIS (ravulizumab-cwvz) - (ICAN) | Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Ongoing | Intravenous | Hematology |
| AstraZeneca PLC | IMFINZI (Durvalumab) + TACE - (EMERALD-3) | Locoregional Hepatocellular carcinoma (HCC) | Phase 3 | Data Released | Intravenous | Oncology |
| AstraZeneca PLC | ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| AstraZeneca PLC | Camizestrant - (SERENA-2) | Advanced ER-positive Breast Cancer | Phase 2 | Data Released | Oral | Oncology |
